Altimmune, Inc. Stock News

Altimmune, Inc. ( ALT ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Vipin Garg - President, CEO & Director Linda Richardson - Chief Commercial Officer Gregory Weaver - Chief Financial Officer M. Roberts - Chief Scientific Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Patrick ...

48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer Cash, cash equivalents and short-term investments of $211 million as of September 30, 2025 Webcast to be...

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for one-on-one meetings at the following investor conferences: Stifel 2025 Healthcare...

Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026 GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc.  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for...

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025.

Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc.  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that 24-week data from it...

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) ...

NEW YORK--(BUSINESS WIRE)-- #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a le...